Pacira Biosciences, Inc.
Pacira BioSciences makes non-opioid pain treatments, best known for EXPAREL, a long-acting local anesthetic injected at the surgical site so patients recover from operations with less reliance on opioids. Its lineup also includes iovera°, a device that uses targeted cold to numb nerves. Founded in 2006 under the placeholder name Blue Acquisition Corp., the Tampa-based company later renamed itself Pacira and rebranded as Pacira BioSciences in 2019.
Granted 261.8K
Granted 54.5K · Sold 7.2K
Granted 54.5K · Sold 23.4K
Granted 99.1K · Sold 62.1K
Granted 52.1K
Granted 19.3K · Sold 11.5K
Granted 6.4K
Granted 6.4K · Sold 500
Granted 6.4K
Granted 6.4K
Granted 6.4K
Granted 6.4K
Sold 2.4K
Granted 6.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Lee Frank D.Chief Executive Officer, Director · 3 transactions | +47.4% | 660.8K | 261.8K | — | — |
| Slonin JonathanChief Medical Officer · 6 transactions | +20.1% | 218.9K | 54.5K | — | 7.2K |
| Williams KristenChief Administrative Officer · 5 transactions | +3.4% | 167.1K | 54.5K | — | 23.4K |
| Cross ShawnChief Financial Officer · 15 transactions | +40.5% | 105.3K | 99.1K | — | 62.1K |
| Teehan BrendanChief Commercial Officer · 3 transactions | +86.9% | 100.9K | 52.1K | — | — |
| Riker LaurenSenior Vice President, Finance · 7 transactions | +4.6% | 62.3K | 19.3K | — | 11.5K |
| Brege LauraDirector · 1 transaction | +27% | 30.1K | 6.4K | — | — |
| Froimson MarkDirector · 2 transactions | +28.6% | 26.5K | 6.4K | — | 500 |
| Christie ChristopherDirector · 1 transaction | +38.5% | 23.1K | 6.4K | — | — |
| Yang Michael J.Director · 1 transaction | +47.8% | 19.8K | 6.4K | — | — |
| Bigal MarceloDirector · 1 transaction | +56.2% | 17.8K | 6.4K | — | — |
| Young AlethiaDirector · 1 transaction | +56.2% | 17.8K | 6.4K | — | — |
| Ceesay AbrahamDirector · 1 transaction | -20.7% | 9.0K | — | — | 2.4K |
| Hirawat SamitDirector · 1 transaction | — | 6.4K | 6.4K | — | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last year: -107.1K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.